Related Experiment Video
Updated: Jun 28, 2026
High Throughput Sequential ELISA for Validation of Biomarkers of Acute Graft-Versus-Host Disease
Published on: October 31, 2012
Quantitative Epstein-Barr virus viral load monitoring in pediatric liver transplantation
1Department of Pediatrics, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
Insights
Implementing quantitative Epstein-Barr virus polymerase chain reaction (qEBV-PCR) monitoring significantly reduced post-transplant lymphoproliferative disease (PTLD) related mortality in pediatric liver transplant recipients. This vital test aids in managing PTLD risks and improving patient survival rates.
Area of Science:
- Pediatric Transplantation
- Virology
- Immunology
Background:
- Post-transplant lymphoproliferative disease (PTLD) is a serious complication following organ transplantation, particularly in children.
- Epstein-Barr virus (EBV) plays a critical role in the pathogenesis of PTLD.
- Early detection and management of EBV infection are crucial for preventing PTLD.
Purpose of the Study:
- To evaluate the impact of implementing quantitative Epstein-Barr virus polymerase chain reaction (qEBV-PCR) testing on PTLD incidence and mortality in pediatric liver transplant recipients.
- To compare outcomes between patients who underwent transplantation before and after the introduction of routine qEBV-PCR monitoring.
Main Methods:
- Retrospective analysis of pediatric liver transplant patients (n=128) from January 1994 to May 2007.
- Division of patients into pre-qEBV-PCR (1994-2002) and post-qEBV-PCR (2003-2007) groups.
- Comparison of EBV infection rates, PTLD incidence, and mortality between the two groups.
Main Results:
- The incidence of primary EBV infection was higher in the post-qEBV-PCR group (33.3%) compared to the pre-qEBV-PCR group (14.0%).
- Incidences of symptomatic EBV infection and PTLD were similar between groups (35.7% vs 31.3% and 9.5% vs 10.5%, respectively).
- PTLD-related mortality was eliminated in the post-qEBV-PCR group, while 5 of 9 PTLD patients died in the pre-qEBV-PCR group. Overall survival improved significantly in the post-qEBV-PCR group (97.6% vs 80.2%).
Conclusions:
- Routine qEBV-PCR monitoring, coupled with immunosuppression modulation, effectively reduces PTLD-related mortality in pediatric liver transplant patients.
- While qEBV-PCR did not decrease PTLD incidence, it enabled timely interventions that prevented fatal outcomes.
- The implementation of qEBV-PCR testing represents a significant advancement in managing EBV-associated risks after pediatric liver transplantation.
Abstract:
The aim of this study was to determine whether the implementation of the quantitative Epstein-Barr virus polymerase chain reaction (qEBV-PCR) test in 2003 decreased the incidence of posttransplant lymphoproliferative disease (PTLD) and PTLD-related mortality. Of the 128 children who underwent liver transplantation between January 1994 and May 2007, 110 (85.9%) survived. Patients were divided into pre (1994 to 2002; n = 86) and post (2003 to 2007; n = 42) EBV-PCR groups. There were no between-group differences in mean age, percentage of patients < 12 months old, or seronegative for EBV. The incidence rates of primary EBV infection in the pre- and post-EBV-PCR groups were 14.0% and 33.3%, respectively (P < .05). In contrast, the pre- and post-EBV-PCR groups showed similar incidences of symptomatic EBV infection (31.3% vs 35.7%; P = .625) and PTLD (10.5% vs 9.5%; P = .869), but different survival rates (80.2% vs 97.6%; P < .001). Five of nine PTLD patients in the pre-EBV-PCR group died of PTLD, but there was no PTLD-related mortality in the post-EBV-PCR group, indicating that PTLD-related mortality decreased after qEBV-PCR monitoring. These findings suggested that frequent EBV viral load monitoring and subsequent modulation of immunosuppression can reduce PTLD and PTLD-related mortality among pediatric liver transplant patients.